Experimental combo aims to revive immune attack on head and neck tumors
NCT ID NCT03019003
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-phase study tested whether combining an oral drug (decitabine) with an immunotherapy (durvalumab) could help people with head and neck cancer whose tumors had stopped responding to standard immunotherapy. Thirteen adults with advanced cancer participated. The goal was to see if the combination was safe and could boost the immune system's ability to fight the cancer. This is not a cure, but an attempt to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.